Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effectiveness of Canadian travel restrictions in reducing burden of SARS-CoV-2 variants of concern

View ORCID ProfileAngela McLaughlin, View ORCID ProfileVincent Montoya, View ORCID ProfileRachel L. Miller, Canadian COVID-19 Genomics Network (CanCOGeN) Consortium, View ORCID ProfileMichael Worobey, View ORCID ProfileJeffrey B. Joy
doi: https://doi.org/10.1101/2023.09.12.23294140
Angela McLaughlin
1British Columbia Centre for Excellence in HIV/AIDS; British Columbia, V6Z 1Y6, Canada
2Bioinformatics, University of British Columbia; British Columbia, V5T 4S6, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Angela McLaughlin
Vincent Montoya
1British Columbia Centre for Excellence in HIV/AIDS; British Columbia, V6Z 1Y6, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vincent Montoya
Rachel L. Miller
1British Columbia Centre for Excellence in HIV/AIDS; British Columbia, V6Z 1Y6, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rachel L. Miller
Michael Worobey
3Department of Ecology and Evolution, University of Arizona; Arizona, 85721, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael Worobey
Jeffrey B. Joy
1British Columbia Centre for Excellence in HIV/AIDS; British Columbia, V6Z 1Y6, Canada
2Bioinformatics, University of British Columbia; British Columbia, V5T 4S6, Canada
4Department of Medicine, University of British Columbia; British Columbia, V5Z 1M9, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jeffrey B. Joy
  • For correspondence: jjoy@bccfe.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Evaluating travel restriction effectiveness in mitigating infectious disease burden is critical for informing public health policy. Here, we quantify where and when variants of SARS-CoV-2 were introduced into Canada to evaluate the extent to which travel restrictions averted viral introductions and COVID-19 case burden. Our results suggest that, across SARS-CoV-2 variants of concern subject to travel restrictions, at least 281 introductions were prevented, accounting for an averted burden of approximately 44,064 cases. This corresponds to approximately 441 averted hospitalizations, 24 averted deaths, and cost savings to Canadian health care systems of approximately 11.2 million Canadian dollars. Travel restrictions were found to be most effective when implemented rapidly during exponential case growth in the focal source and when global circulation was limited. Our analyses reveal that COVID-19 travel restrictions mitigated case burdens and highlight their value in future pandemic response.

Summary COVID-19 travel restrictions against variants worked and were most effective when implemented rapidly and preceding new variants’ wider circulation.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

AM was supported by a Canada Graduate Scholarship Doctoral Award from the Canadian Institutes for Health Research. AM, VM, RLM, and JBJ received funding from the British Columbia Centre for Excellence in HIV/AIDS and Providence Healthcare. MW was supported by funding from the Centers of Excellence for Influenza Research and Response (CEIRR). JBJ was supported by an operating grant from the Canadian Institutes of Health Research Coronavirus Rapid Response Programme grant number 440371 and a Canadian Institutes for Health Research Variant of Concern Grant.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

Viral genome sequences analyzed in this study were sourced from the Global initiative on sharing all influenza data (GISAID) coronavirus (CoV) database and are subject to the GISAID EpiFlu Database Access Agreement. Within this agreement, we cannot distribute data to any third part other than Authorized Users. A full set of all subsampled genome sequence accession IDs is available at GISAID EPI_SET_230510yr (doi:10.55876/gis8.230510yr), which serves as the data acknowledgement for all originating and submitting laboratories. Those without GISAID access credentials may retrieve information about all data contributors by either clicking on the DOI or pasting the EPI_SET ID in the "Data Acknowledgement Locator" on the GISAID homepage. Full and subsampled alignments can be shared to Authorized Users upon request. Scripts used for data curation, inferences, analyses, and visualization are available at github.com/AngMcL/sars-cov-2_variants_canada.

https://www.github.com/AngMcL/sars-cov-2_variants_canada

https://doi.org/10.55876/gis8.230510yr

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 14, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness of Canadian travel restrictions in reducing burden of SARS-CoV-2 variants of concern
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effectiveness of Canadian travel restrictions in reducing burden of SARS-CoV-2 variants of concern
Angela McLaughlin, Vincent Montoya, Rachel L. Miller, Canadian COVID-19 Genomics Network (CanCOGeN) Consortium, Michael Worobey, Jeffrey B. Joy
medRxiv 2023.09.12.23294140; doi: https://doi.org/10.1101/2023.09.12.23294140
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Effectiveness of Canadian travel restrictions in reducing burden of SARS-CoV-2 variants of concern
Angela McLaughlin, Vincent Montoya, Rachel L. Miller, Canadian COVID-19 Genomics Network (CanCOGeN) Consortium, Michael Worobey, Jeffrey B. Joy
medRxiv 2023.09.12.23294140; doi: https://doi.org/10.1101/2023.09.12.23294140

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (579)
  • Anesthesia (139)
  • Cardiovascular Medicine (1944)
  • Dentistry and Oral Medicine (252)
  • Dermatology (184)
  • Emergency Medicine (333)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (698)
  • Epidemiology (11100)
  • Forensic Medicine (8)
  • Gastroenterology (623)
  • Genetic and Genomic Medicine (3164)
  • Geriatric Medicine (308)
  • Health Economics (561)
  • Health Informatics (2042)
  • Health Policy (863)
  • Health Systems and Quality Improvement (782)
  • Hematology (310)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12717)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2985)
  • Nursing (164)
  • Nutrition (463)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1550)
  • Ophthalmology (477)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (402)
  • Pediatrics (912)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2782)
  • Public and Global Health (5590)
  • Radiology and Imaging (1093)
  • Rehabilitation Medicine and Physical Therapy (632)
  • Respiratory Medicine (759)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (289)
  • Surgery (343)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (132)